Intellectual Property

Hatch-Waxman Patent Litigation

Matters

Representative cases include:

  • Everett Laboratories, Inc. v. Acella Pharmaceuticals, LLC, Nos. 1:13-cv-04294, 1:13-cv-03529, 1:13-cv-03487 and 1:13-cv-03470 (D.N.J. 2013). Defeated three motions for a preliminary injunction in a pharmaceutical patent case involving prenatal nutritional supplements, which led to the withdrawal of the remaining motion for a preliminary injunction.
  • Novartis Pharmaceuticals Corporation v. Actavis LLC et al, No. 2:13-cv-01028 (D.N.J. 2013)
  • Horizon Pharma AG et al v. Watson Laboratories, Inc. - Florida et al, No. 1:13-cv-05124 (D.N.J. 2013)
  • Novartis Pharmaceuticals Corporation et al v. Wockhardt USA LLC et al, No. 2:12-cv-03967 (D.N.J. 2012)
  • Astrazeneca Pharmaceuticals LP et al v. Lupin Ltd. et al, No. 3:12-cv-06888 (D.N.J. 2012). Settled case on terms favorable for our client.
  • Teva Women's Health, Inc. v. Lupin, Ltd., No. 12-01577 (Fed. Cir. 2012). Court held in favor of our client that the evidence of prima facie obviousness was strong and invalidated the patent. The case has been appealed to the Federal Circuit.
  • Warner Chilcott Company, LLC v. Lupin, Ltd. et al, No. 3:11-cv-07228 (D.N.J. 2011) Court held in favor of our client that the evidence of prima facie obviousness was strong and invalidated the chewable oral contraceptives patent number 6,667,050.
  • Astrazeneca AB et al v. Dr. Reddy's Laboratories Inc. et al, No. 3:11-cv-02317 (D.N.J. 2011). Settled case on terms favorable for our client.
  • Gilead Sciences, Inc. v. Sigmapharm Laboratories, LLC, No. 2:10-cv-04931 (D.N.J. 2010). Settled case on terms favorable for our client.
  • The Medicines Company v. Teva Parenteral Medicines, Inc., No. 09-CV-750-ER (D. Del. 2009). Served as Special Master to the Court.
  • Tyco Healthcare Group LP et al v. Pharmaceutical Holdings Corporation et al, No. 2:07-cv-01299 (D.N.J. 2007). Court granted summary judgment in favor of our client’s claim of prima facie obviousness. The case has been appealed to the Federal Circuit.